171 related articles for article (PubMed ID: 18805907)
1. Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots.
Liapis E; McLuckie KI; Lewis PD; Farmer PB; Brown K
Nucleic Acids Res; 2008 Oct; 36(18):5933-45. PubMed ID: 18805907
[TBL] [Abstract][Full Text] [Related]
2. DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by alpha-acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells.
McLuckie KI; Routledge MN; Brown K; Gaskell M; Farmer PB; Roberts GC; Martin EA
Biochemistry; 2002 Jul; 41(28):8899-906. PubMed ID: 12102632
[TBL] [Abstract][Full Text] [Related]
3. Mutation spectra induced by alpha-acetoxytamoxifen-DNA adducts in human DNA repair proficient and deficient (xeroderma pigmentosum complementation group A) cells.
McLuckie KI; Crookston RJ; Gaskell M; Farmer PB; Routledge MN; Martin EA; Brown K
Biochemistry; 2005 Jun; 44(22):8198-205. PubMed ID: 15924439
[TBL] [Abstract][Full Text] [Related]
4. Mutagenic potential of alpha-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen.
Terashima I; Suzuki N; Shibutani S
Cancer Res; 1999 May; 59(9):2091-5. PubMed ID: 10232593
[TBL] [Abstract][Full Text] [Related]
5. Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells.
Besaratinia A; Pfeifer GP
Biochemistry; 2005 Jun; 44(23):8418-27. PubMed ID: 15938631
[TBL] [Abstract][Full Text] [Related]
6. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.
Shibutani S; Ravindernath A; Suzuki N; Terashima I; Sugarman SM; Grollman AP; Pearl ML
Carcinogenesis; 2000 Aug; 21(8):1461-7. PubMed ID: 10910945
[TBL] [Abstract][Full Text] [Related]
7. Detection of tamoxifen-DNA adducts on lacI genes using DNA polymerase stop assay.
Cheng RH; Gant TW
Changgeng Yi Xue Za Zhi; 1999 Jun; 22(2):189-96. PubMed ID: 10493022
[TBL] [Abstract][Full Text] [Related]
8. Genotoxic mechanism of tamoxifen in developing endometrial cancer.
Kim SY; Suzuki N; Laxmi YR; Shibutani S
Drug Metab Rev; 2004 May; 36(2):199-218. PubMed ID: 15237851
[TBL] [Abstract][Full Text] [Related]
9. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.
Kim SY; Suzuki N; Laxmi YR; McGarrigle BP; Olson JR; Sharma M; Sharma M; Shibutani S
Chem Res Toxicol; 2005 May; 18(5):889-95. PubMed ID: 15892583
[TBL] [Abstract][Full Text] [Related]
10. Site-specific tamoxifen-DNA adduct formation: lack of correlation with mutational ability in Escherichia coli.
Lowes DA; Brown K; Heydon RT; Martin EA; Gant TW
Biochemistry; 1999 Aug; 38(34):10989-96. PubMed ID: 10460153
[TBL] [Abstract][Full Text] [Related]
11. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry.
Gamboa da Costa G; Marques MM; Beland FA; Freeman JP; Churchwell MI; Doerge DR
Chem Res Toxicol; 2003 Mar; 16(3):357-66. PubMed ID: 12641436
[TBL] [Abstract][Full Text] [Related]
12. Identification of hepatic tamoxifen-DNA adducts in mice: alpha-(N(2)-deoxyguanosinyl)tamoxifen and alpha-(N(2)-deoxyguanosinyl)tamoxifen N-oxide.
Umemoto A; Monden Y; Suwa M; Kanno Y; Suzuki M; Lin CX; Ueyama Y; Momen MA; Ravindernath A; Shibutani S; Komaki K
Carcinogenesis; 2000 Sep; 21(9):1737-44. PubMed ID: 10964106
[TBL] [Abstract][Full Text] [Related]
13. Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice.
Umemoto A; Komaki K; Monden Y; Suwa M; Kanno Y; Kitagawa M; Suzuki M; Lin CX; Ueyama Y; Momen MA; Ravindernath A; Shibutani S
Chem Res Toxicol; 2001 Aug; 14(8):1006-13. PubMed ID: 11511174
[TBL] [Abstract][Full Text] [Related]
14. Lack of genotoxicity of tamoxifen in human endometrium.
Carmichael PL; Ugwumadu AH; Neven P; Hewer AJ; Poon GK; Phillips DH
Cancer Res; 1996 Apr; 56(7):1475-9. PubMed ID: 8603387
[TBL] [Abstract][Full Text] [Related]
15. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
[TBL] [Abstract][Full Text] [Related]
16. Identification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxytamoxifen.
Dasaradhi L; Shibutani S
Chem Res Toxicol; 1997 Feb; 10(2):189-96. PubMed ID: 9049430
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
18. Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.
Phillips DH; Hewer A; Osborne MR; Cole KJ; Churchill C; Arlt VM
Mutagenesis; 2005 Jul; 20(4):297-303. PubMed ID: 15928012
[TBL] [Abstract][Full Text] [Related]
19. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen.
Shibutani S; Suzuki N; Laxmi YR; Schild LJ; Divi RL; Grollman AP; Poirier MC
Cancer Res; 2003 Aug; 63(15):4402-6. PubMed ID: 12907611
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo.
Beland FA; McDaniel LP; Marques MM
Carcinogenesis; 1999 Mar; 20(3):471-7. PubMed ID: 10190564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
